NEWS AND EVENTS
November 2022
AJK Biopharmaceutical published " Broad-spectrum antibacterial activity alone and in combination with antibiotics." J. Med. Chem. 2022, (SEE DETAILS)
​
September 2022
AJK Biopharmaceutical Team Participate in World AMR (Antimicrobial Resistance) Congress
​
August 2022
NIH Awarded a Gant to AJK Biopharmaceutical for “ Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria.
​
April 2022
AJK Biopharmaceutical filed a patent " Synthetic Antimicrobial peptides, US Patent App. 17/639,082, 2022. (SEE DETAILS)
​
March 2022
AJK Biopharmaceutical published "Amphiphilic cyclic peptide [W 4 KR 5]-antibiotics combinations as broad-spectrum antimicrobial agents. Eur. J. Med. Chem., 2022, 17, 235:114278. DOI:10.1016/j.ejmech.2022.114278. PMID: 35347995.
​
November 2021
AJK Biopharmaceutical filed a patent " Compositions and methods for nucleic acid delivery.PCT Int. Appl. (2021), WO 2021134026 A2 20210701.
​
October 2021
AJK Biopharmaceutical published " Small Amphiphilic Peptides: Activity Against Broad Range of Drug-Resistant Bacteria and Structural Insight into Membranolytic Properties. J. Med. Chem. 2022, 65, 665-687. doi:10.1021/acs.jmedchem.1c01782. PMID: 34978443.
​
August 2021
AJK Biopharmaceutical filed a patent "Amphiphilic peptides for nucleic acid and protein delivery. August 4, 2021, US 63/229,149 "
​
April 2021
AJK Biopharmaceutical filed a patent " Synthetic antimicrobial peptides PCT Int. Appl. (2021), WO 2021042039 A1 20210304.(SEE DETAILS)
​
Feb 2021
AJK Biopharmaceutical published " Synthesis and antiviral activity of fatty acyl conjugates of Remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. European Journal of Medicinal Chemistry, 2021, 226, 113862, (SEE DETAILS).
​
May 2020
AJK Biopharmaceutical published " Comparative antiviral activity of Remdesivir and anti-HIV nucleoside analogs against human coronavirus 229E (HCoV-229E). Molecules (2020) 25(10), 2343; ( SEE DETAILS )
